Organization (Industry)
INSULET CORP
ClinicalTrials.gov lists INSULET CORP as lead sponsor of 23 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers INSULET CORP: 23 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 31 |
| Diabetes Mellitus, Type 1 | 21 |
| Diabetes Mellitus, Type 2 | 6 |
| Hypoglycemia | 2 |
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 5 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=15) | 20% on time (n=15) |
Journals published in (10)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes technology & therapeutics | 4 |
| Diabetes care | 3 |
| BMJ open diabetes research & care | 1 |
| Diabetes | 1 |
| Diabetes research and clinical practice | 1 |
Showing 5 of 10 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 192 | 118 | 2025-12-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 2,708,100,000 | 247,100,000 | 301,100,000 |
| 2024 | 2,071,600,000 | 418,300,000 | 219,600,000 |
| 2023 | 1,697,100,000 | 206,300,000 | 205,000,000 |
| 2022 | 1,305,300,000 | 4,600,000 | 180,200,000 |
| 2021 | 1,098,800,000 | 16,800,000 | 160,100,000 |
| 2020 | 904,400,000 | 6,800,000 | 146,800,000 |
| 2019 | 738,200,000 | 11,600,000 | 132,300,000 |
| 2018 | 563,800,000 | 3,300,000 | 94,800,000 |
| 2017 | 463,800,000 | -26,800,000 | 75,700,000 |
| 2016 | 366,989,000 | -28,879,000 | 55,710,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (29)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-13 | Other financing | not disclosed | Sec extracted |
| 2025-06-06 | Debt financing | not disclosed | Sec extracted |
| 2025-06-06 | Debt financing | not disclosed | Sec extracted |
| 2025-03-20 | Debt financing | 444,000,000 | Sec extracted |
| 2025-03-20 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 29 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 10 |
FDA recalls (21)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Omnipod 5 Pods. Includes the below Model/REF Numbers: 1. POD-OMNI-I1-6720. 2. POD-OMNI-I1-6220. 3. OMNI-I1-6729 (10-Pack), OMNI-I1-6720 (Single Pod). 4. OMNI-I1-6220. 5. OMNI-I1-6720. 6. BLE-H1-529 (10-Pack), BLE-H1-520 (Single Pod). | Class I | 2026-05-20 |
| Omnipod DASH Pod. Includes the below Model/REF Numbers: 1. POD-BLE-I1-525 (5-Pack), POD-BLE-I1-520 (Single Pod). 2. POD-BLE-I1-529 (10-Pack), POD-BLE-I1-520 (Single Pod). 3. BLE-I1-529 (10-Pack), BLE-I1-520 (Single Pod). 4. BLE-C1-529 (10-Pack), BLE-C1-520 (Single Pod). | Class I | 2026-05-20 |
| Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420 (Single Pod). | Class I | 2026-05-20 |
| Omnipod 5 Pods. Model/Catalog number: PT-001662 ASM 5PK Pod STRL OPS G6G7 | Class I | 2026-03-12 |
| The failure occurs if a user on the Omnipod 5 iOS application selects and holds down on a manual entry field, to magnify the visual field using the magnifying feature of the iPhone, while simultaneously selecting a single number on the keyboard. | Class II | 2025-09-11 |
Showing 5 of 21 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2026-02-05 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Insulet Corporation | Acton, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (18)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Abbott Laboratories | Co sponsors trial with | 5 |
| University of Virginia | Co sponsors trial with | 3 |
| University of California System | Co sponsors trial with | 2 |
| Luxembourg Institute of Health | Co sponsors trial with | 1 |
| Medtronic plc | Co sponsors trial with | 1 |
Showing 5 of 18 relationships.
Latest dated events (285)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-20 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-20 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-20 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 285 events.
Biomarker capability evidence (47)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| AICDA | Trial sponsor | Named in trial inclusion criteria |
| DPP4 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 47 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.